Tianma Gouteng Yin as Adjunctive Treatment for Essential Hypertension: A Systematic Review of Randomized Controlled Trials

Table 7

Analyses of TCM zheng.

Trials		Intervention (n/N)	Control (n/N)	RR [95% CI]	P Value
TGY plus ACEI versus ACEI
modified TGY plus captopril versus captopril	1	48/50	36/48	8.00 [1.68, 38.00]	0.009
TGY plus captopril versus captopril	1	38/40	28/40	8.14 [1.69, 39.22]	0.009
modified TGY plus captopril versus captopril	1	44/48	21/32	5.76 [1.64, 20.25]	0.006
TGY plus perindopril versus perindopril	1	29/30	23/30	8.83 [1.01, 76.96]	0.05
TGY plus captopril versus captopril	1	47/50	38/50	4.95 [1.30, 18.81]	0.02
TGY plus captopril versus captopril	1	47/50	39/50	4.42 [1.15, 16.97]	0.03
Meta-Analysis	6	253/268	185/250	6.15 [3.38, 11.18]	<0.00001
TGY plus CCB versus CCB
modified TGY plus amlodipine besylate versus amlodipine besylate	1	42/46	26/40	5.65 [1.68, 19.04]	0.005
TGY plus levamlodipine versus levamlodipine	1	55/60	40/60	5.50 [1.90, 15.89]	0.002
Meta-Analysis	2	97/106	66/100	5.56 [2.50, 12.37]	<0.0001
TGY plus “CCB + ACEI” versus “CCB + ACEI”
modified TGY plus amlodipine besylate and lisinopril versus amlodipine besylate and lisinopril	1	29/30	22/30	10.55 [1.23, 90.66]	0.03
Meta-Analysis	1	29/30	22/30	10.55 [1.23, 90.66]	0.03